14.30-16.00 |
SO 01 LITHIUM MEDICINE OR MYTH |
|
| Chair: T. DINAN (Ireland) S. MONTGOMERY (UK) |
||
| 14.30-15.00 | SO 0101 Lithium in acute treatment of bipolar disorder Rasmus LICHT (Denmark) |
|
| 15.00-15.30 | SO 0102 Bipolar maintenance treatment Heinz GRUNZE (United Kingdom) |
|
| 15.30-16.00 | SO 0103 Lithium: Still the gold standard for augmenting antidepressants? Timothy DINAN (Ireland) |
|
16.00-16.30 |
Coffee break |
|
16.30-18.00 |
SO 02 THE HURTFUL BRAIN |
|
| Chair: J. DEN BOER (The Netherlands) R. LICHT (Denmark) |
||
| 16.30-17.00 | SO 0201 The comorbidity of pain, anxiety and depression Hans-Ulrich WITTCHEN (Germany) |
|
| 17.00-17.30 | SO 0202 Explaining the co-occurrence of pain, anxiety and depression Johan DEN BOER (The Netherlands) |
|
| 17.30-18.00 | SO 0203 Psychotropics as treatments for pain Michael BACH (Germany) |
|
18.00-19.00 |
Opening Ceremony |
09.00-10.30 |
SO 03 RECOVERY – THE NEW TREATMENT
|
|
| Moderator: A. WADE (UK) | ||
| 09.00-09.10 | Welcome and introduction | |
| 09.10-09.30 | SO 0301 Is recovery a better treatment goal than remission? Koen DEMYTTENAERE (Belgium), Thomas E. SCHLÄPFER (Germany) |
|
| 09.35-09.55 | SO 0302 What assessment tools should be used for evaluating whether the treatment goal has been achieved? Koen DEMYTTENAERE (Belgium), Thomas E. SCHLÄPFER (Germany) |
|
| SO 0303 What would be the best approach to changing treatment for patients not achieving the treatment goal upon antidepressant therapy? Koen DEMYTTENAERE (Belgium), Thomas E. SCHLÄPFER (Germany) |
||
| 10.25-10.30 | Discussion and closing remarks | |
| All sessions will be followed by a 5’ session of Questions and Answers chaired by Alan WADE (UK) |
||
10.30-11.00 |
Coffee break |
|
11.00-12.30 |
SO 04 COGNITION AS A TREATMENT
|
|
| Chair: H.J. MÖLLER (Germany) D. BALDWIN (UK) |
||
| 11.00-11.30 | SO 0401The treatment of cognitive impairment in OCD Naomi FINEBERG (UK) |
|
| 11.30-12.00 | SO 0402 The treatment of cognitive deficits in MDD David BALDWIN (UK) |
|
| 12.00-12.30 | SO 0403 Cognitive deficits in bipolar disorder Eduard VIETA (Spain) |
|
12.30-13.30 |
Lunch |
|
13.30-15.00 |
SO 05 COGNITIVE DYSFUNCTION IN
|
|
| Chair: M. DORAISWAMY (USA) | ||
| 13.30-13.35 | Welcome and introduction | |
| 13.35-14.00 | SO 0501 Do patients and physicians have the same perceptions of cognitive symptoms in depression? Lawrence MARTIN (Canada) |
|
| 14.00-14.25 | SO 0502 Cognitive dysfunction in depressed patients: prevalence, risks and consequences Barbara SAHAKIAN (UK) |
|
| 14.25-14.50 | SO 0503 Assessment of cognitive dysfunction in depression Murali DORAISWAMY (USA) |
|
| 14.50-15.00 | Discussion and closing remarks | |
15.00-16.30 |
SO 06 DEPRESSION, COGNITIVE AND NEGATIVE SYMPTOMS IN SCHIZOPHRENIA: UNDERLYING NEUROBIOLOGY AND NOVEL LEADS FOR PHARMACOLOGICAL TREATMENT |
|
| Chair: S. KASPER (Austria) J. LOFTUS (Monaco) |
||
| 15.00-15.30 | SO 0601 Do depressive cognitive and negative symptoms impact on outcome in schizophrenia? Hans-Juergen MOELLER (Germany) |
|
| 15.30-16.00 | SO 0602 Neurobiological mechanisms and novel targets for cognitive improvement Torgny SVENSSON (Sweden) |
|
| 16.00-16.30 | SO 0603 Antidepressant drugs in schizophrenia and antipsychotic drugs in depression: basic and clinical perspective Siegfried KASPER (UK) |
|
16.30-16.45 |
Coffee break |
|
16.45-18.15 |
SO 07 ADHERENCE WITH TREATMENT |
|
| Chair: C. ALTAMURA (Italy) H.P. VOLZ (Germany) |
||
| 16.45-17.15 | SO 0701 Compliance counselling in bipolar disorder Carla TORRENT (Spain) |
|
| 17.15-17.45 | SO 0702The treatment of cognitive deficits in MDD Hans-Peter VOLZ (Germany) |
|
| 17.45-18.15 | SO 0703Are any drug formulations inherently better for adherence? Carlo ALTAMURA (Italy) |
|
|
|
09.00-10.30 |
SO 08 – THE REVISED DIAGNOSTIC CRITERIA OF MENTAL DISORDERS (DSM-5):BIPOLAR DISORDER IS BIPOLAR AGAIN – REVISITING THE CLASSICS |
|
| Chair: M. DAVIDSON (Israel) | ||
| 09.00-09.10 | Welcome and introduction SO 0801 DSM-5 – a critical appraisal Michael DAVIDSON (Israel) |
|
| 09.10-09.30 | SO 0802 DSM-5 criteria for bipolar disorder: what has changed? Alan SWANN (USA) |
|
| 09.30-10.00 | SO 0803 Implications for clinical management: State of the art treatment of mixed Mania – New data Eduard VIETA (Spain) |
|
| 10.00-10.30 | Panel discussion Closing remarks | |
10.30-11.00 |
Coffee break |
|
11.00-12.30 |
SO 09 – TREATMENT RESISTANT DEPRESSION |
|
| Chair: S. MONTGOMERY (UK) S. KASPER (Austria) |
||
| 11.00-11.30 | SO 0901 Is resistant depression a signal for bipolar disorder? Alessandro SERRETTI (Italy) |
|
| 11.30-12.00 | SO 0902 My preferred treatments in TRD Stuart A. MONTGOMERY (UK) |
|
| 12.00-12.30 | SO 0903 New finding in resistant depression – focus on anxiety comorbidity Joseph ZOHAR (Israel) |
|
12.30-13.30 |
Lunch |
|
13.30-15.00 |
SO 10 – TREATMENT OF MDD |
|
| Chair: E. ERIKSSON (Sweden) A. SERRETTI (Italy) |
||
| 13.30-14.00 | SO 1001 The effect of comorbid anxiety on outcomes in MDD Borwin BANDELOW (Germany) |
|
| 14.00-14.30 | SO 1002 Does being elderly alter response in MDD? Cornelius KATONA (UK) |
|
| 14.30-15.00 | SO 1003 Double standards when evaluating the evidence base for CBT and pharmacological treatment, respectively: a critical analysis of guidelines from NICE and other bodies Elias ERIKSSON (Sweden) |
|
|
|
|
| Chair: B. BANDELOW (Germany) C. KATONA (UK) |
||
| 15.00-15.30 | SO 1101 Behavioural Addictions in adult ADHD Pierre-Michel LLORCA (France) |
|
| 15.30-14.00 | SO 1102 Biomarkers and prediction of response in MDD – an update Dietmar WINKLER (Austria) |
|
| 14.00-14.30 | SO 1103 Neuropeptide Y and CRH in MDD Aleksander A. MATHÉ (Sweden) |
